Table 4:

Comparison of reported treatment and adverse effects in animal studies that used genipin for SXL. Listed are the animal model, number of injections (Inj), time interval between injections, concentration (Conc), volume (Vol) of each injection, and the total administered dose of genipin, along with the reported treatment effects and adverse effects.

Study	Model	Inj	Interval	Conc	Vol	Total Dose	Reported Treatment Effects	Reported Adverse Effects
Wang and Corpuz (2015)	Guinea pig	3	7 Days	22 mM	100 μl	1.49 mg	Significant decrease in FD myopia and axial length.	No observed histological damage. Significant thickening of scleral collagen fibrils.
Liu and Wang (2017)	Rabbit	4	2–3 Days	0.5 mM	500 μl	0.22 mg	Significant increase in tissue stiffness.	No observed histological damage.
Hannon et al. (2019, 2020)	Rat	1	-	15 mM	150 μl	0.50 mg	Significant increase in tissue stiffness.	No significant effect on retinal and visual function. Reduced axons in the optic nerve.
El Hamdaoui et al. (2021) and current	Tree shrew	3	2 Days	10 mM	400 μl	2.70 mg	No significant effect on FD myopia and axial elongation.	Significant RNFL thinning and corneal thickening.
		3	2 Days	20 mM	400 μl	5.43 mg	Significant effect on FD myopia but no effect on axial elongation.	Compromised retinal function, significant RNFL thinning and corneal thickening.
		5	2 Days	20 mM	400 μl	9.04 mg	Significant effect on FD myopia and axial elongation.	Compromised retinal function, significant RNFL thinning and corneal thickening.